Stay in the know
Receive timely insights and briefings from HSF Kramer, tailored to keep you informed and ahead
Subscribe now
Herbert Smith Freehills Kramer (HSF Kramer) is pleased to be advising CSL on its recently announced proposed demerger of its Seqirus business (Seqirus) as a standalone ASX-listed entity by the end of Financial Year 2026.
Seqirus is one of the world’s largest influenza vaccine providers, dedicated to advancing public health through innovative vaccine solutions and pandemic preparedness.
The HSF Kramer team is led by partners Priscilla Bryans, Baden Furphy, Alexander Mackinnon, and Michael Ziegelaar, with partner Ryan Leslie advising on the tax aspects of the transaction.
Key contacts
Priscilla Bryans
Partner, Melbourne
Baden Furphy
Partner, Melbourne
Alexander Mackinnon
Partner, Melbourne
Michael Ziegelaar
Partner, Melbourne
Ryan Leslie
Partner, Melbourne
Media contact
For further information on this news article, please contact:
Gina Baldassarre
External Communications Manager
Sydney
More news
19 June 2026
HSF Kramer hosts 7th Africa Arbitration Academy
Herbert Smith Freehills Kramer's London International Arbitration and Africa practices welcomed delegates from across the African continent for the …
19 June 2026
Hiswara Bunjamin & Tandjung advises Indonesia’s Danantara Investment Management on US$1.5 billion bond issuance
Leading Indonesian law firm Hiswara Bunjamin & Tandjung (HBT) has advised PT Danantara Investment Management (DIM), the investment arm of Indonesia's …
19 June 2026
Herbert Smith Freehills Kramer advises Axight on the acquisition of Estia Health as part of a Stonepeak-led consortium
HSF Kramer has advised Axight – an Abu Dhabi-based private equity investment manager focused on the Asia-Pacific region – on its acquisition of a …